Multi-targeted kinase inhibitor sorafenib and its future

Malgorzata Gil, Saravut (John) Weroha, Renuka Iyer, Mateusz Opyrchal

Research output: Contribution to journalReview article

Abstract

Sorafenib is an oral, small-molecule receptor, tyrosine kinase inhibitor with antiproliferative as well as antiangiogenic properties. The multiple cellular targets of sorafenib include serine/threonine kinase Raf, vascular endothelial growth factor receptors 1, 2, 3, platelet-derived growth factor-b, Flt-3, and c-Kit. Sorafenib has demonstrated preclinical activity against several tumor types and has been approved for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and iodine-refractory thyroid carcinoma. In this review we summarize the clinical antitumor activity of sorafenib in solid tumors, with focus on breast, ovarian, and glioblastoma cancers. We review available data from multiple phase Ib and phase II trials with sorafenib alone or in combination with other agents, and highlight the most encouraging clinical data which will guide the future directions of research. We also discuss biomarker research and the need for better predictive markers for response to sorafenib. Although sorafenib is relatively well tolerated, there are multiple toxicities that can result in dose reductions and discontinuations that are especially evident in combination therapy trials. In the next several years new data from large phase III trials will become available, which might broaden the clinical indication of sorafenib to adjuvant settings and/or other malignancies. Better understanding of its mechanism of action and clinical activity will assist in clinical management of patients.

Original languageEnglish (US)
Pages (from-to)16-24
Number of pages9
JournalCancer and Chemotherapy Reviews
Volume10
Issue number1
StatePublished - 2015

Fingerprint

Phosphotransferases
Vascular Endothelial Growth Factor Receptor-1
Vascular Endothelial Growth Factor Receptor-2
Neoplasms
sorafenib
Protein-Serine-Threonine Kinases
Platelet-Derived Growth Factor
Receptor Protein-Tyrosine Kinases
Glioblastoma
Thyroid Neoplasms
Renal Cell Carcinoma
Research
Iodine
Ovarian Neoplasms
Hepatocellular Carcinoma
Breast
Biomarkers
Therapeutics

Keywords

  • Angiogenesis
  • Breast cancer
  • Glioblastoma
  • Ovarian cancer
  • Sorafenib
  • Tyrosine kinase inhibitor (TKI)

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Multi-targeted kinase inhibitor sorafenib and its future. / Gil, Malgorzata; Weroha, Saravut (John); Iyer, Renuka; Opyrchal, Mateusz.

In: Cancer and Chemotherapy Reviews, Vol. 10, No. 1, 2015, p. 16-24.

Research output: Contribution to journalReview article

Gil, M, Weroha, SJ, Iyer, R & Opyrchal, M 2015, 'Multi-targeted kinase inhibitor sorafenib and its future', Cancer and Chemotherapy Reviews, vol. 10, no. 1, pp. 16-24.
Gil, Malgorzata ; Weroha, Saravut (John) ; Iyer, Renuka ; Opyrchal, Mateusz. / Multi-targeted kinase inhibitor sorafenib and its future. In: Cancer and Chemotherapy Reviews. 2015 ; Vol. 10, No. 1. pp. 16-24.
@article{e39a3c14d76e421fa9f78ac97c5529f7,
title = "Multi-targeted kinase inhibitor sorafenib and its future",
abstract = "Sorafenib is an oral, small-molecule receptor, tyrosine kinase inhibitor with antiproliferative as well as antiangiogenic properties. The multiple cellular targets of sorafenib include serine/threonine kinase Raf, vascular endothelial growth factor receptors 1, 2, 3, platelet-derived growth factor-b, Flt-3, and c-Kit. Sorafenib has demonstrated preclinical activity against several tumor types and has been approved for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and iodine-refractory thyroid carcinoma. In this review we summarize the clinical antitumor activity of sorafenib in solid tumors, with focus on breast, ovarian, and glioblastoma cancers. We review available data from multiple phase Ib and phase II trials with sorafenib alone or in combination with other agents, and highlight the most encouraging clinical data which will guide the future directions of research. We also discuss biomarker research and the need for better predictive markers for response to sorafenib. Although sorafenib is relatively well tolerated, there are multiple toxicities that can result in dose reductions and discontinuations that are especially evident in combination therapy trials. In the next several years new data from large phase III trials will become available, which might broaden the clinical indication of sorafenib to adjuvant settings and/or other malignancies. Better understanding of its mechanism of action and clinical activity will assist in clinical management of patients.",
keywords = "Angiogenesis, Breast cancer, Glioblastoma, Ovarian cancer, Sorafenib, Tyrosine kinase inhibitor (TKI)",
author = "Malgorzata Gil and Weroha, {Saravut (John)} and Renuka Iyer and Mateusz Opyrchal",
year = "2015",
language = "English (US)",
volume = "10",
pages = "16--24",
journal = "Cancer and Chemotherapy Reviews",
issn = "1885-740X",
publisher = "Publicaciones Permanyer",
number = "1",

}

TY - JOUR

T1 - Multi-targeted kinase inhibitor sorafenib and its future

AU - Gil, Malgorzata

AU - Weroha, Saravut (John)

AU - Iyer, Renuka

AU - Opyrchal, Mateusz

PY - 2015

Y1 - 2015

N2 - Sorafenib is an oral, small-molecule receptor, tyrosine kinase inhibitor with antiproliferative as well as antiangiogenic properties. The multiple cellular targets of sorafenib include serine/threonine kinase Raf, vascular endothelial growth factor receptors 1, 2, 3, platelet-derived growth factor-b, Flt-3, and c-Kit. Sorafenib has demonstrated preclinical activity against several tumor types and has been approved for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and iodine-refractory thyroid carcinoma. In this review we summarize the clinical antitumor activity of sorafenib in solid tumors, with focus on breast, ovarian, and glioblastoma cancers. We review available data from multiple phase Ib and phase II trials with sorafenib alone or in combination with other agents, and highlight the most encouraging clinical data which will guide the future directions of research. We also discuss biomarker research and the need for better predictive markers for response to sorafenib. Although sorafenib is relatively well tolerated, there are multiple toxicities that can result in dose reductions and discontinuations that are especially evident in combination therapy trials. In the next several years new data from large phase III trials will become available, which might broaden the clinical indication of sorafenib to adjuvant settings and/or other malignancies. Better understanding of its mechanism of action and clinical activity will assist in clinical management of patients.

AB - Sorafenib is an oral, small-molecule receptor, tyrosine kinase inhibitor with antiproliferative as well as antiangiogenic properties. The multiple cellular targets of sorafenib include serine/threonine kinase Raf, vascular endothelial growth factor receptors 1, 2, 3, platelet-derived growth factor-b, Flt-3, and c-Kit. Sorafenib has demonstrated preclinical activity against several tumor types and has been approved for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and iodine-refractory thyroid carcinoma. In this review we summarize the clinical antitumor activity of sorafenib in solid tumors, with focus on breast, ovarian, and glioblastoma cancers. We review available data from multiple phase Ib and phase II trials with sorafenib alone or in combination with other agents, and highlight the most encouraging clinical data which will guide the future directions of research. We also discuss biomarker research and the need for better predictive markers for response to sorafenib. Although sorafenib is relatively well tolerated, there are multiple toxicities that can result in dose reductions and discontinuations that are especially evident in combination therapy trials. In the next several years new data from large phase III trials will become available, which might broaden the clinical indication of sorafenib to adjuvant settings and/or other malignancies. Better understanding of its mechanism of action and clinical activity will assist in clinical management of patients.

KW - Angiogenesis

KW - Breast cancer

KW - Glioblastoma

KW - Ovarian cancer

KW - Sorafenib

KW - Tyrosine kinase inhibitor (TKI)

UR - http://www.scopus.com/inward/record.url?scp=84941096202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941096202&partnerID=8YFLogxK

M3 - Review article

VL - 10

SP - 16

EP - 24

JO - Cancer and Chemotherapy Reviews

JF - Cancer and Chemotherapy Reviews

SN - 1885-740X

IS - 1

ER -